Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: Three-year results (The Advanz Trial): A randomized, controlled trial

AIDS Research and Human Retroviruses

Volumn 26, Issue 7, 2010, Pages 747-757

  Miró, José M ^a   Manzardo, Christian ^a   Pich, Judith ^a   Domingo, Pere ^b   Ferrer, Elena ^a   Arribas, José R ^c   Ribera, Esteban ^d   Arrizabalaga, Julio ^e   Loncá, Montserrat ^a   Cruceta, Anna ^a   De Lazzari, Elisa ^a   Fuster, Montserrat ^b   Podzamczer, Daniel ^a   Plana, Montserrat ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA VIRUS; VIRUS LOAD; BLOOD; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954898622     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0105     Document Type: Article

References (28)

1. Girardi E, Sabin CA, and Monforte AD: Late diagnosis of HIV infection: Epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007;46(Suppl 1):S3-S8.
2. Sabin CA, Smith CJ, Gumley H, et al.: Late presenters in the era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy. AIDS 2004;18:2145-2151.
3. Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, and Boyd S: Late diagnosis of HIV infection: Trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr 2006;43:491-494.
4. Sobrino Vegas P, García San Miguel L, Caro-Murillo AM, et al.: CoRIS Delayed diagnosis of HIV infection in a multi-center cohort: Prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009;7:224-230.
5. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al.: and the HIV Outpatient Study Investigators: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4\+ cell strata. Ann Intern Med 2003;138:620-626.
6. Hammer SM, Erron J Jr, Reiss P, et al.: and the International AIDS Society-USA panel: Treatment for adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
7. Manzardo C, Zaccarelli M, Agü ero F, Antinori A, and Miró JM: Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007;46(Suppl 1):S9-S18.
8. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
9. Chou R, Fu R, Huffman LH, and Korthuis PT: Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: Discrepancies between direct and indirect meta-analyses. Lancet 2006; 368:1503-1515.
10. Soria A and Lazzarin A: Antiretroviral treatment strategies and immune reconstitution in treatment-nä?ve HIV-infected patients with advanced disease. J Acquir Immune Defic Syndr 2007;46(Suppl 1):S19-S30.
11. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 8; 41(RR-17): 1-19.
12. Libois A, Lopez A, Garcia F, et al.: Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 2006;22:657-666.
13. AIDS Clinical Trials Group: Table for grading severity of adult adverse experiences. August 1992. Accessed April 7, 2009, at http://aactg.s-3.com/ members/adulttox. htm.
14. Bartlett JA, De Masia R, Quinn J, et al.: Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-1377.
15. Arribas JR, Pulido F, Miró, JM, et al.: High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/ml and opportunistic diseases: The EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS 2002;16:1554-1556.
16. Mezzaroma I, Carlesimo M, Pinter E, et al.: Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999;13: 1187-1193.
17. Gea-Benacloche JC and Clifford Lane H: Immune recon-stitution in HIV infection. AIDS 1999;13(Suppl A):S25-S38.
18. Liu Z, Cumberland WG, Hultin LE, et al.: Elevated CD38 antigen expression on CD8\+ T-cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4\+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.
19. Giorgi JV, Hultin LE, McKeating JA, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179:859-870.
20. Orendi JM, Bloem AC, Borleffs JC, et al.: Activation and cell cycle antigens in CD4\+ and CD8\+ T-cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998;178:1279-1287.
21. Carbone J, Gil J, Benito JM, et al.: Increased levels of activated subsets of CD4 T-cells add to the prognostic value of low CD4 T-cell counts in a cohort of HIV-infected drug users. AIDS 2000;14:2823-2829.
22. Leng Q, Borkow G, Weisman Z, Stein M, Kalinkovich A, and Bentwich Z: Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr 2001;27:389-397.
23. Shepard BD, Loufty MR, Raboud J, et al.: Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. J Acquir Immune Defic Syndr 2008;45:149-155.
24. Pulido F, Arribas JR, Miró JM, et al.: EfaVIP Cohort Study Group. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active anti-retroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004;35:343-350.
25. Pulido F, Arribas JR, Moreno S, et al.: Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir-based HAART in a large cohort of antiretroviral-nä?ve patients with advanced HIV infection. [P9] Presented at the 8th International Congress on Drug Therapy in HIV Infection, 2006, Glasgow.
26. \+ Arnaiz JA, Mallolas J, Podzamczer D, et al.:BEST Study Team.Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS2003;17:831-840
27. Arnaiz JA, Mallolas J, Podzamczer D, et al.: BEST Study Team. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-840.
28. Voigt E, Wickesberg A, Wasmuth JC, et al.: First-line ritonavir/indinavir 100/800mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med 2002;3:277-282.